- Home
- AGEN vs GLU Comparison
AGEN vs GLU Comparison
Compare AGEN & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- GLU
- Stock Information
- Founded
- AGEN 1994
- GLU 2004
- Country
- AGEN United States
- GLU United States
- Employees
- AGEN N/A
- GLU N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GLU Finance/Investors Services
- Sector
- AGEN Health Care
- GLU Finance
- Exchange
- AGEN Nasdaq
- GLU Nasdaq
- Market Cap
- AGEN 96.2M
- GLU 92.2M
- IPO Year
- AGEN 2000
- GLU N/A
- Fundamental
- Price
- AGEN $3.32
- GLU $16.05
- Analyst Decision
- AGEN Buy
- GLU
- Analyst Count
- AGEN 3
- GLU 0
- Target Price
- AGEN $10.50
- GLU N/A
- AVG Volume (30 Days)
- AGEN 357.6K
- GLU 12.4K
- Earning Date
- AGEN 03-13-2025
- GLU 01-01-0001
- Dividend Yield
- AGEN N/A
- GLU 8.60%
- EPS Growth
- AGEN N/A
- GLU N/A
- EPS
- AGEN N/A
- GLU 0.62
- Revenue
- AGEN $160,427,000.00
- GLU N/A
- Revenue This Year
- AGEN N/A
- GLU N/A
- Revenue Next Year
- AGEN $26.02
- GLU N/A
- P/E Ratio
- AGEN N/A
- GLU $22.50
- Revenue Growth
- AGEN 59.00
- GLU N/A
- 52 Week Low
- AGEN $2.50
- GLU $11.61
- 52 Week High
- AGEN $19.69
- GLU $15.40
- Technical
- Relative Strength Index (RSI)
- AGEN 45.96
- GLU 60.55
- Support Level
- AGEN $3.09
- GLU $15.64
- Resistance Level
- AGEN $3.68
- GLU $16.28
- Average True Range (ATR)
- AGEN 0.25
- GLU 0.33
- MACD
- AGEN -0.03
- GLU 0.07
- Stochastic Oscillator
- AGEN 23.00
- GLU 77.23
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.